Skip to content

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

Improving Decision-Making Encounters in Lung Cancer (I DECide): A Low-Literacy Conversation Tool

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04946279
Enrollment
98
Registered
2021-06-30
Start date
2020-08-07
Completion date
2026-12-31
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Brief summary

This clinical trial refines and tests the effect of a decision aid in improving decision-making in patients with non-small cell lung cancer. Patients with cancer want to be informed about their diagnoses, treatment procedures and goals of treatment. They also seek active roles in decision-making. Shared decision-making (SDM) is the process of clinician and patient jointly participating in a health decision after discussing the options, benefits and harms, and considering the patient's values, preferences, and circumstances. SDM can improve patient involvement in decision making, satisfaction, health care quality, and quality of life. Decision aids can improve patient knowledge, create more realistic outcome expectations; reduce decisional conflict, distress, depression and uncertainty; and improve physician-patient communication and quality of life, compared with no decision aid. This trial's main aim is to evaluate the feasibility and efficacy of a decision aid in patients with non-small cell lung cancer.

Detailed description

PRIMARY OBJECTIVES: I. Refine a conversation tool among patients with lung cancer by conducting prototype testing in an iterative process. II. Conduct a trial at two comprehensive cancer treatment centers representing academic and Veterans Affairs medical centers. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive the conversation tool. ARM II: Patients receive usual care. Patients in both arms are followed up within 4-8 weeks after baseline to complete a second questionnaire.

Interventions

OTHERBest Practice

Receive usual/standard of care

OTHERInformational Intervention

Receive conversation tool

OTHERQuestionnaire Administration

Ancillary studies - Baseline and follow-up questionnaires

Sponsors

Oregon Health and Science University
CollaboratorOTHER
ATS Foundation
CollaboratorUNKNOWN
Hildegard Lamfrom Endowment
CollaboratorUNKNOWN
Medical Research Foundation, Oregon
CollaboratorOTHER
OHSU Knight Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* PART I: Completed treatment for suspected or confirmed stage I-IV non-small cell lung cancer (NSCLC) * PART I: English fluency * PART II: Undergoing diagnostic work-up for suspected stage I-IV NSCLC * PART II: English fluency * PART II: \> 6-month life expectancy * PART II: Score of \> 3 on the 6-Item Screener for Cognitive Impairment

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the conversation toolAt enrollmentThe number of patients enrolled divided by the number of patients offered enrollment.
Acceptability of the conversation toolAt enrollmentThe number of participants who completed the conversation tool divided by the number of participants who began the conversation tool.

Secondary

MeasureTime frameDescription
Shared decision-making qualityAt the end of follow-up at 8 weeksAssessed using the Shared Decision Making Questionnaire.
AnxietyFrom enrollment to the end of follow-up at 8 weeksAssessed using the Hospital Anxiety and Depression Scale.
Decisional conflictAt the end of follow-up at 8 weeksAssessed using the Decisional Conflict Scale.
Decisional RegretAt the end of follow-up at 8 weeksAssessed using the Decisional Regret Scale.
Self-efficacyFrom enrollment to the end of follow-up at 8 weeksAssessed using the Decision Self-Efficacy Scale.
Values-treatment concordanceFrom enrollment to the end of follow-up at 8 weeksAssessed using electronic medical record (EMR).
Decision making involvementFrom enrollment to the end of follow-up at 8 weeksAssessed using the Control Preferences Scale.
Perceived involvement in careAt the end of follow-up at 8 weeksAssessed using the Perceived Involvement in Care Scale.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026